Jazz Pharma Asks Fed. Circ. To Reverse Orange Book Delisting
Jazz Pharmaceuticals Inc. has urged the Federal Circuit to undo a federal injunction forcing it to delist a narcolepsy drug-related patent from the U.S. Food and Drug Administration's Orange Book, a database of...To view the full article, register now.
Already a subscriber? Click here to view full article